Literature DB >> 10383374

Increasing resistance of Brucellae to co-trimoxazole.

A Kinsara, A Al-Mowallad, A O Osoba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10383374      PMCID： PMC89318     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  1 in total

1.  Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis.

Authors:  J M Montejo; I Alberola; P Glez-Zarate; A Alvarez; J Alonso; A Canovas; C Aguirre
Journal:  Clin Infect Dis       Date:  1993-05       Impact factor: 9.079
  1 in total
  10 in total

1.  Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family.

Authors:  Martine Braibant; Laurence Guilloteau; Michel S Zygmunt
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 2.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

3.  Antimicrobial susceptibilities of Brucella isolates from various clinical specimens.

Authors:  Yasemin Bayram; Hanifi Korkoca; Cenk Aypak; Mehmet Parlak; Aytekin Cikman; Selcuk Kilic; Mustafa Berktas
Journal:  Int J Med Sci       Date:  2011-03-03       Impact factor: 3.738

4.  In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014 - 2015.

Authors:  Anand Deshmukh; Ferry Hagen; Ola Al Sharabasi; Mariamma Abraham; Godwin Wilson; Sanjay Doiphode; Muna Al Maslamani; Jacques F Meis
Journal:  BMC Microbiol       Date:  2015-06-16       Impact factor: 3.605

5.  Antimicrobial susceptibility of Brucella melitensis in Kazakhstan.

Authors:  Alexandr Shevtsov; Marat Syzdykov; Andrey Kuznetsov; Alexandr Shustov; Elena Shevtsova; Kalysh Berdimuratova; Kasim Mukanov; Yerlan Ramankulov
Journal:  Antimicrob Resist Infect Control       Date:  2017-12-28       Impact factor: 4.887

6.  Preparation and Evaluation of Rifampicin and Co-trimoxazole-loaded Nanocarrier against Brucella melitensis Infection

Authors:  Narges Bodaghabadi; Samira Hajigholami; Ziba Vaise Malekshahi; Maliheh Entezari; Farhood Najafi; Hadi Shirzad; Majid Sadeghizadeh
Journal:  Iran Biomed J       Date:  2017-10-15

7.  Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.

Authors:  Javier Ariza; Mile Bosilkovski; Antonio Cascio; Juan D Colmenero; Michael J Corbel; Matthew E Falagas; Ziad A Memish; Mohammad Reza Hasanjani Roushan; Ethan Rubinstein; Nikolaos V Sipsas; Javier Solera; Edward J Young; Georgios Pappas
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

8.  In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology.

Authors:  Selcuk Kilic; Murat Dizbay; Kenan Hizel; Dilek Arman
Journal:  Braz J Microbiol       Date:  2008-06-01       Impact factor: 2.476

9.  In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China.

Authors:  Zhi-Guo Liu; Dong-Dong Di; Miao Wang; Ri-Hong Liu; Hong-Yan Zhao; Dong-Ri Piao; Zhong-Zhi Zhao; Yong-Qing Hao; Ya-Nan Du; Hai Jiang; Bu-Yun Cui; Xian-Zhu Xia
Journal:  BMC Infect Dis       Date:  2018-01-16       Impact factor: 3.090

10.  Antimicrobial susceptibility of Brucella spp. isolated from Iranian patients during 2016 to 2018.

Authors:  Saeed Alamian; Maryam Dadar; Afshar Etemadi; Davoud Afshar; Mohammad Mehdi Alamian
Journal:  Iran J Microbiol       Date:  2019-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.